Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New daily pill shows promise for weight loss in phase 2 trial

NCT ID NCT06828055

Disease control Sponsor: Viking Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental daily pill, VK2735, to help adults with obesity or overweight (plus a weight-related health issue) lose weight. About 280 participants took either the pill or a placebo for 13 weeks. The main goal was to see how much weight they lost and if the pill was safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

280 people

The number who actually took part.

Started

Dec 2024

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent. 2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2 * Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. * BMI calculated at the Screening visit will be used to determine eligibility. Exclusion Criteria: 1. History of or current clinically significant medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation 2. Self-reported body weight change of 5% or more within 3 months of screening 3. Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational) 4. Current or past diagnosis of chronic pancreatitis 5. Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened) 6. Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening 7. Any prescription or over-the-counter medications intended for weight loss within 6 months of screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Weight loss

Contacts and locations

Locations

  • Viking Clinical Site #100

    Indianapolis, Indiana, 46260, United States

  • Viking Clinical Site #101

    Clearwater, Florida, 33756, United States

  • Viking Clinical Site #102

    Port Orange, Florida, 32127, United States

  • Viking Clinical Site #103

    Knoxville, Tennessee, 37909, United States

  • Viking Clinical Site #104

    Austin, Texas, 78705, United States

  • Viking Clinical Site #105

    Lake Forest, California, 96230, United States

  • Viking Clinical Site #106

    San Antonio, Texas, 78229, United States

  • Viking Clinical Site #107

    Ocoee, Florida, 34761, United States

  • Viking Clinical Site #108

    Largo, Florida, 33777, United States

  • Viking Clinical Site #109

    City of Saint Peters, Missouri, 63303, United States

  • Viking Clinical Site #110

    Louisville, Kentucky, 40213, United States

  • Viking Clinical Site #111

    Peoria, Arizona, 85381, United States

  • Viking Clinical Site #112

    Kansas City, Missouri, 64131, United States

  • Viking Clinical Site #113

    Butte, Montana, 59701, United States

  • Viking Clinical Site #114

    Marrero, Louisiana, 70072, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.